Literature DB >> 28229073

Epidemiology and Risk Factors of Cholangiocarcinoma.

Martha M Kirstein1, Arndt Vogel1.   

Abstract

BACKGROUND: Cholangiocarcinoma (CCA) is the second most common primary liver cancer, being characterized by its late diagnosis and fatal outcome. Recent epidemiological reports indicate an increasing worldwide incidence of intrahepatic CCA but a decreasing incidence of extrahepatic CCA.
METHODS: In this review, we present an overview of the incidence and epidemiology of CCA and possible strategies for screening and surveillance.
RESULTS: Efficient strategies for the screening and surveillance of CCA have not been established so far. The vast majority of CCA occur sporadically without any apparent cause; however, several risk factors such as liver flukes, chronic biliary and liver diseases, and lifestyle-related aspects causing chronic inflammation and cholestasis in the liver have been linked to the development of CCA. These risk factors likely contribute to the increased incidence observed in some countries and also explain the wide geographical differences in the incidence of CCA.
CONCLUSION: Several risk factors for CCA have been identified. Given the dismal prognosis of advanced CCA, regular surveillance examinations with a combination of ultrasonography and laboratory tests appear to be useful in patients at risk and need to be explored in prospective trials.

Entities:  

Keywords:  Cholangiocarcinoma; Epidemiology; Risk factors; Screening; Surveillance

Year:  2016        PMID: 28229073      PMCID: PMC5290446          DOI: 10.1159/000453013

Source DB:  PubMed          Journal:  Visc Med        ISSN: 2297-4725


  71 in total

1.  Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation.

Authors:  K M Boberg; A Bergquist; S Mitchell; A Pares; F Rosina; U Broomé; R Chapman; O Fausa; T Egeland; G Rocca; E Schrumpf
Journal:  Scand J Gastroenterol       Date:  2002-10       Impact factor: 2.423

2.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

3.  Potential diagnostic and prognostic biomarkers for cholangiocarcinoma in serum and bile.

Authors:  Bin Wang; Liang Chen; Hao-Teng Chang
Journal:  Biomark Med       Date:  2016-05-27       Impact factor: 2.851

4.  Hepatic and extrahepatic malignancies in primary sclerosing cholangitis.

Authors:  Annika Bergquist; Anders Ekbom; Rolf Olsson; Dan Kornfeldt; Lars Lööf; Ake Danielsson; Rolf Hultcrantz; Stefan Lindgren; Hanne Prytz; Hanna Sandberg-Gertzén; Sven Almer; Fredrik Granath; Ulrika Broomé
Journal:  J Hepatol       Date:  2002-03       Impact factor: 25.083

5.  Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans.

Authors:  Hashem B El-Serag; Eric A Engels; Ola Landgren; Elizabeth Chiao; Louise Henderson; Harshinie C Amaratunge; Thomas P Giordano
Journal:  Hepatology       Date:  2009-01       Impact factor: 17.425

6.  Sex-specific and race/ethnicity-specific disparities in cholangiocarcinoma incidence and prevalence in the USA: An updated analysis of the 2000-2011 Surveillance, Epidemiology and End Results registry.

Authors:  Sasan Mosadeghi; Benny Liu; Taft Bhuket; Robert J Wong
Journal:  Hepatol Res       Date:  2015-11-12       Impact factor: 4.288

7.  Incidence and prognosis of cholangiocarcinoma in Danish patients with and without inflammatory bowel disease: a national cohort study, 1978-2003.

Authors:  Rune Erichsen; Peter Jepsen; Hendrik Vilstrup; Anders Ekbom; Henrik Toft Sørensen
Journal:  Eur J Epidemiol       Date:  2009-06-26       Impact factor: 8.082

8.  Rising trends in cholangiocarcinoma: is the ICD classification system misleading us?

Authors:  Shahid A Khan; Shireen Emadossadaty; Nimzing G Ladep; Howard C Thomas; Paul Elliott; Simon D Taylor-Robinson; Mireille B Toledano
Journal:  J Hepatol       Date:  2011-12-13       Impact factor: 25.083

9.  Monolobar Caroli's Disease and cholangiocarcinoma.

Authors:  E K Abdalla; C E Forsmark; G Y Lauwers; J N Vauthey
Journal:  HPB Surg       Date:  1999

10.  The antecedents of biliary cancer: a primary care case-control study in the United Kingdom.

Authors:  M J Grainge; J West; M Solaymani-Dodaran; G P Aithal; T R Card
Journal:  Br J Cancer       Date:  2008-11-18       Impact factor: 7.640

View more
  43 in total

Review 1.  Cholangiocarcinoma: novel therapeutic targets.

Authors:  Keisaku Sato; Shannon Glaser; Domenico Alvaro; Fanyin Meng; Heather Francis; Gianfranco Alpini
Journal:  Expert Opin Ther Targets       Date:  2020-02-26       Impact factor: 6.902

Review 2.  [Personalized treatment of cholangiocellular carcinoma (CCA)].

Authors:  L Jödicke; L Zender; N P Malek
Journal:  Internist (Berl)       Date:  2020-02       Impact factor: 0.743

3.  GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinoma.

Authors:  Sonia Brun; Firas Bassissi; Cindy Serdjebi; Marie Novello; Jennifer Tracz; François Autelitano; Marie Guillemot; Philippe Fabre; Jérôme Courcambeck; Christelle Ansaldi; Eric Raymond; Philipe Halfon
Journal:  Invest New Drugs       Date:  2019-02-19       Impact factor: 3.850

Review 4.  Development and Characterization of Human Primary Cholangiocarcinoma Cell Lines.

Authors:  Abdulkadir Isidan; Ali Yenigun; Daiki Soma; Eric Aksu; Kevin Lopez; Yujin Park; Arthur Cross-Najafi; Ping Li; Debjyoti Kundu; Michael G House; Sanjukta Chakraborty; Shannon Glaser; Lindsey Kennedy; Heather Francis; Wenjun Zhang; Gianfranco Alpini; Burcin Ekser
Journal:  Am J Pathol       Date:  2022-05-28       Impact factor: 5.770

Review 5.  Update in Contrast-Enhanced Ultrasound.

Authors:  Steffen Beckmann; Jörg H Simanowski
Journal:  Visc Med       Date:  2020-11-26

Review 6.  Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.

Authors:  Alphonse E Sirica; Mario Strazzabosco; Massimiliano Cadamuro
Journal:  Adv Cancer Res       Date:  2020-12-09       Impact factor: 6.242

7.  The Prognostic Value of the CA19-9/TBIL Ratio in Patients with Biliary Tract Cancers (BTCs): A Retrospective Study.

Authors:  Jianchun Xiao; Li Wang; Tao Hong; Binglu Li; Wei Liu; Qiang Qu; Chaoji Zheng; Xiaodong He
Journal:  J Oncol       Date:  2021-02-23       Impact factor: 4.375

8.  Progranulin modulates cholangiocarcinoma cell proliferation, apoptosis, and motility via the PI3K/pAkt pathway.

Authors:  Minerva Daya; Watcharin Loilome; Anchalee Techasen; Malinee Thanee; Prakasit Sa-Ngiamwibool; Attapol Titapun; Puangrat Yongvanit; Nisana Namwat
Journal:  Onco Targets Ther       Date:  2018-01-18       Impact factor: 4.147

9.  Cholangiocarcinoma: anatomical location-dependent clinical, prognostic, and genetic disparities.

Authors:  Hualian Hang; Seogsong Jeong; Meng Sha; Defu Kong; Zhifeng Xi; Ying Tong; Qiang Xia
Journal:  Ann Transl Med       Date:  2019-12

Review 10.  Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice?

Authors:  Alice Boilève; Marc Hilmi; Matthieu Delaye; Annemilaï Tijeras-Raballand; Cindy Neuzillet
Journal:  Cancers (Basel)       Date:  2021-05-30       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.